← Leaderboards
Stacey C Sigmon
University Of Vermont & St Agric College
$13,535,861
Attributed
$13,535,861
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,535,861 · 8
By mechanism
R01$7,171,540 · 3
U54$3,477,580 · 1
P20$1,143,638 · 1
R34$651,938 · 1
P30$641,922 · 1
R03$449,243 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Gary S. Stein$24,489,599
- Jan Kirk Carney$9,034,139
- Kelly Jean Cowan$3,118,052
- Leslie W Young$1,279,720
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseParticipantDesignBehavior TherapyAbstinenceBaseProgramsCostVermontResearch PersonnelPrevalenceDoseReportingFundingRandomizedScienceBehaviorProbabilitySmokerResearch DesignBehavioral EconomicsSmokingBehavioral PharmacologyBuprenorphine
Grant awards (30)
CORE B: Behavioral Economics and Intervention Science (BEIS) Core$213,974
P30 · FY2025 · GM · contact PI
CORE B: Behavioral Economics and Intervention Science (BEIS) Core$213,974
P30 · FY2024 · GM · contact PI
CORE B: Behavioral Economics and Intervention Science (BEIS) Core$213,974
P30 · FY2023 · GM · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Abusers$679,807
U54 · FY2022 · DA · contact PI
Behavioral Economics and Intervention Science$287,167
P20 · FY2022 · GM · contact PI
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluation$751,483
R01 · FY2021 · DA · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Abusers$684,684
U54 · FY2021 · DA · contact PI
Behavioral Economics and Intervention Science$163,649
P20 · FY2021 · GM · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Abusers$689,560
U54 · FY2020 · DA · contact PI
Behavioral Economics and Intervention Science$255,123
P20 · FY2020 · GM · contact PI
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluation$751,483
R01 · FY2019 · DA · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Abusers$695,640
U54 · FY2019 · DA · contact PI
Behavioral Economics and Intervention Science$231,300
P20 · FY2019 · GM · contact PI
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluation$751,483
R01 · FY2018 · DA · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Abusers$727,889
U54 · FY2018 · DA · contact PI
Behavioral Economics and Intervention Science$206,399
P20 · FY2018 · GM · contact PI
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluation$751,483
R01 · FY2017 · DA · contact PI
Interim Treatment: Leveraging buprenophine + technology to bridge waitlist delays$325,969
R34 · FY2015 · DA · contact PI
Interim Treatment: Leveraging buprenophine + technology to bridge waitlist delays$325,969
R34 · FY2014 · DA · contact PI
Incentive-based smoking cessation for methadone patients$328,960
R01 · FY2011 · DA · contact PI
Incentive-based smoking cessation for methadone patients$379,463
R01 · FY2010 · DA · contact PI
Individual differences in stimulant reinforcement as a function of DRD2 allele$223,493
R03 · FY2010 · DA · contact PI
Effective Treatment for Prescription Opioid Abuse$605,943
R01 · FY2009 · DA · contact PI
Incentive-based smoking cessation for methadone patients$377,749
R01 · FY2009 · DA · contact PI
Individual differences in stimulant reinforcement as a function of DRD2 allele$225,750
R03 · FY2009 · DA · contact PI
Effective Treatment for Prescription Opioid Abuse$609,225
R01 · FY2008 · DA · contact PI
Incentive-based smoking cessation for methadone patients$318,540
R01 · FY2008 · DA · contact PI
Effective Treatment for Prescription Opioid Abuse$617,093
R01 · FY2007 · DA · contact PI
Incentive-based smoking cessation for methadone patients$351,219
R01 · FY2007 · DA · contact PI
Effective Treatment for Prescription Opioid Abuse$577,416
R01 · FY2006 · DA · contact PI